Skip header and navigation

2 records – page 1 of 1.

Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment.

https://arctichealth.org/en/permalink/ahliterature101528
Source
Int J Technol Assess Health Care. 2011 Jul;27(3):193-200
Publication Type
Article
Date
Jul-2011
Author
Gisela Kobelt
Ingrid Lekander
Andrea Lang
Bernd Raffeiner
Costantino Botsios
Pierre Geborek
Author Affiliation
Lund University and European Health Economics.
Source
Int J Technol Assess Health Care. 2011 Jul;27(3):193-200
Date
Jul-2011
Language
English
Publication Type
Article
Abstract
Objectives: To explore the cost-effectiveness of early biologic treatment, followed by dose-reduction in the case of remission, of active rheumatoid arthritis (RA), compared with standard treatment with methotrexate (MTX) in Sweden.Methods: Effectiveness (function, disease activity, erosions) in early RA for both alternatives was taken from a clinical trial comparing etanercept (ETA) combined with MTX to MTX alone. Patients discontinuing treatment can switch to another or their first biologic treatment. For patients in remission (Disease Activity Score [DAS28]
PubMed ID
21736857 View in PubMed
Less detail

Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).

https://arctichealth.org/en/permalink/ahliterature133529
Source
Calcif Tissue Int. 2011 Sep;89(3):234-45
Publication Type
Article
Date
Sep-2011
Author
Erik Landfeldt
Andrea Lang
Sean Robbins
Oskar Ström
Author Affiliation
Innovus, Stockholm, Sweden, erik.landfeldt@innovus.com.
Source
Calcif Tissue Int. 2011 Sep;89(3):234-45
Date
Sep-2011
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Alendronate - administration & dosage - adverse effects - therapeutic use
Bone Density Conservation Agents - administration & dosage - adverse effects - therapeutic use
Drug Substitution - statistics & numerical data
Drug-Related Side Effects and Adverse Reactions - epidemiology
Etidronic Acid - administration & dosage - adverse effects - analogs & derivatives - therapeutic use
Female
Gastrointestinal Diseases - chemically induced - epidemiology
Gastrointestinal Tract - drug effects - physiology
Humans
Male
Medication Adherence - statistics & numerical data
Middle Aged
Organometallic Compounds - administration & dosage - adverse effects - therapeutic use
Osteoporosis - drug therapy - epidemiology - physiopathology
Raloxifene - administration & dosage - adverse effects - therapeutic use
Registries
Retrospective Studies
Sweden
Thiophenes - administration & dosage - adverse effects - therapeutic use
Abstract
The objective of this study was to describe and analyze the gastrointestinal tolerability and medication switching in patients receiving treatment for primary osteoporosis in Sweden. The study was based on all patients starting therapy with alendronate, risedronate, strontium ranelate, and raloxifene in Sweden between 2005 and 2009. The primary outcome measure was start of treatment with a gastroprotective agent, and the secondary outcome was hospitalization for a gastrointestinal adverse event (GIAE). Switching was analyzed while patients were on treatment. The crude incidence of gastroprotective treatment during the first 6 months after initiation of osteoporosis therapy was 5.14%, 5.93%, 4.25%, and 2.86% for patients prescribed alendronate, risedronate, strontium ranelate, and raloxifene, respectively. Patients prescribed raloxifene had a significantly lower risk of filling a prescription for a gastroprotective agent compared with alendronate. There was no significant difference in the risk of hospitalization for GIAEs. Less than 3% switched therapy while on treatment. Patients prescribed risedronate, strontium ranelate, and raloxifene had a significantly higher risk of switching compared with patients taking alendronate. In conclusion, no significant difference in the incidence of GIAEs was found between patients prescribed alendronate, risedronate, and strontium ranelate. Individuals prescribed raloxifene had a significantly lower risk of GIAEs compared with patients prescribed alendronate. No significant difference was found in the frequency of hospitalization for GIAEs. Switching between osteoporosis medications and drug classes was uncommon. Prescribers should consider the real-world gastrointestinal safety of osteoporosis drugs when choosing between treatment options to potentially improve medication adherence and consequently effectiveness.
PubMed ID
21695544 View in PubMed
Less detail